Skip to main content
PlainMeds

What the label lists and what reports show

Bevacizumab side effects

Bevacizumab's FDA label: “Most common adverse reactions incidence (incidence > 10%) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.” FAERS holds 128,715 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is diarrhoea (7,477 reports).

  • No generic listed

Check it at the source: the bevacizumab FDA label on DailyMed (effective March 23, 2026, Amneal Pharmaceuticals LLC); the FDA FAERS public dashboard.

What does the label list?

From the label: adverse reactions

Most common adverse reactions incidence (incidence > 10%) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.

Table 4: Grades 1 - 4 Adverse Reactions Occurring at Higher Incidence (≥ 5%) in Patients…

Adverse Reaction aBevacizumab with Chemotherapy (N=218)Chemotherapy (N=222)
Fatigue80%75%
Peripheral edema15%22%
Decreased appetite34%26%
Hyperglycemia26%19%
Hypomagnesemia24%15%
Weight loss21%7%
Hyponatremia19%10%
Hypoalbuminemia16%11%
Hypertension29%6%
Thrombosis10%3%
Urinary tract infection22%14%
Infection10%5%
Headache22%13%
Dysarthria8%1%
Anxiety17%10%
Epistaxis17%1%
Increased blood creatinine16%10%
Proteinuria10%3%
Stomatitis15%10%
Proctalgia6%1%
Anal fistula6%0%
Pelvic pain14%8%
Neutropenia12%6%
Lymphopenia12%5%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued

The following clinically significant adverse reactions are described elsewhere in the labeling: Gastrointestinal Perforations and Fistulae [see Warnings and Precautions (5.1)]. Surgery and Wound Healing Complications [see Warnings and Precautions (5.2)]. Hemorrhage [see Warnings and Precautions (5.3)]. Arterial Thromboembolic Events [see Warnings and Precautions (5.4)]. Venous Thromboembolic Events [see Warnings and Precautions (5.5)]. Hypertension [see Warnings and Precautions (5.6)]. Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.7)]. Renal Injury and Proteinuria [see Warnings and Precautions (5.8)]. Infusion-Related Reactions [see Warnings and Precautions (5.9)]. Ovarian Failure [see Warnings and Precautions (5.11)]. Congestive Heart Failure [see Warnings and Precautions (5.12)]. Most common adverse reactions incidence (incidence > 10%) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Source: FDA drug label, Amneal Pharmaceuticals LLC, effective March 23, 2026 (SPL set 6b4040a2-a5c5-4ff0-ab45-935d7e49cf78), via openFDA; the full label on DailyMed

What do FAERS reports show?

128,715 reports list bevacizumab among the medicines taken, each a report of something that happened, not proof the medicine caused it; 28,571 are coded as a death and 40,640 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 21 reactions below, 12 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

  • Off Label Use (a use or a product term, not a reaction)15,099
  • Death (an outcome recorded in the report)13,462
  • Disease Progression (a use or a product term, not a reaction)7,582
  • Diarrhoea (named in the label)7,477
  • Nausea (named in the label)6,676
  • Fatigue (named in the label)6,642
  • Hypertension (named in the label)6,109
  • Vomiting (named in the label)5,061
  • Anaemia4,472
  • Pyrexia4,145
  • Neutropenia (named in the label)4,104
  • Asthenia (named in the label)3,698
  • Decreased Appetite (named in the label)3,535
  • Dyspnoea3,498
  • Thrombocytopenia3,443
  • Drug Ineffective (a use or a product term, not a reaction)3,326
  • Proteinuria (named in the label)3,141
  • Neuropathy Peripheral3,039
  • Abdominal Pain (named in the label)2,947
  • Malignant Neoplasm Progression2,773
  • Headache (named in the label)2,430
  • Platelet Count Decreased2,403
  • Rash2,399
  • Constipation (named in the label)2,397
  • Pain2,374

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Bevacizumab: the full record
label, generics, price, shortages, recalls
Side effects hub
the most reported medicines and reactions